Year-End Report 18/19

September 2018 – August 2019, Diamyd Medical AB (publ), Fiscal year 2018/2019To preserve and regain the body’s own insulin productionDiamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B.Further information is available on https://www.diamyd.com Figures in parentheses relate to the corresponding period previous financial year. September 1, 2018 – August 31, 2019 ·  Net income: MSEK 1.6 (0.8), whereof the fourth quarter MSEK 0.3 (0.1). The change refers to increased sales of GAD-protein for pre-clinical research. ·  Net result: MSEK -